RecruitingPhase 3NCT03131726
Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)
Sponsor
Lund University
Enrollment
80 participants
Start Date
Jan 26, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy treated with simvastatin or no treatment.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- Age 18-70 years
- Active mild to moderate with at least one sign of mild GO (NO SPECS class 2a and b) with reference to Colour Atlas at EUGOGO website (www.eugogo.eu). Exophthalmos up to 24 mm with a disease duration of \<18 months (as recorded by the patient)
- Graves´ disease with clinical and laboratory euthyroidism after stopping treatment with anti thyroid drugs (ATD), or 2 months treatment with ATD, or euthyroid 6 months after treatment with radioiodine, or euthyroid after total thyroidectomy. Clinical and laboratory euthyroidism is defined as normal fT4, fT3 and TSH below the upper limit of the local reference interval and no clinical symptoms or signs of hyperthyroidism. L-thyroxine is used to achieve euthyroidism during the study period.
Exclusion Criteria13
- Pregnancy or breast-feeding
- Previous treatment of Graves´ ophthalmopathy
- Severe Graves ophthalmopathy requiring corticosteroid treatment, retrobulbar irradiation, orbital decompression surgery
- Current or previous treatment with simvastatin or other statins (within 3 months)
- Allergy (skin rash or systemic reactions) to statins
- Congestive heart failure
- Renal insufficiency (glomerular filtration rate \<60 ml/min)
- ASAT or ALAT \> 2.5 times the upper limit of the local laboratory
- Alcoholism as judged by local criteria
- Coagulopathy including treatment with warfarin or new oral anti-coagulation drugs
- Previous or current gastric ulcer
- Inflammatory bowel disease diabetic retinopathy or nephropathy
- Trauma within 10 days
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSimvastatin 40mg
see arm description
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03131726
Related Trials
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
NCT074807201 location
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
NCT056783741 location
Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy
NCT071245721 location
Bimatoprost as a Treatment for Graves' Orbitopathy
NCT037086271 location
Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
NCT065902201 location